About Oncorus

Realizing the Full Promise of Viral Immunotherapies

Welcome to Oncorus. We are a biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients.

While immunotherapies have improved outcomes for some patients, many patients unfortunately are not eligible for, or do not respond to, existing immunotherapies. At Oncorus, our goal is to enable more patients to respond to this revolutionary approach of harnessing the body’s immune system to tackle cancer.
We are advancing a pipeline of intratumorally and intravenously administered product candidates for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and our Synthetic Virus Platform. Our viral immunotherapies are designed to selectively attack and kill tumor cells and deliver transgenes to stimulate multiple arms of the immune system against tumors.

Our personal stories of cancer’s insidious impact on the lives of our loved ones, friends, colleagues, and, in some cases, even ourselves, motivates us each day to drive forward our mission to realize the full promise of viral immunotherapy for cancer patients.

Our Team

We have assembled a seasoned leadership team with extensive experience in developing and manufacturing oncology therapies, including advancing product candidates from preclinical research through clinical development and commercialization. We invite you learn more about our leadership team, including our personal ties to cancer, which serve as sources of inspiration and motivate us in our important work.

Ted Ashburn, MD, PhD

President & CEO
Director
Learn More

John McCabe, MBA

Chief Financial Officer
Learn More

John Goldberg, MD

Senior Vice President of Clinical Development
Learn More

Lorena Lerner, PhD

Vice President of Molecular Biology
Learn More

Christophe Quéva, PhD

Chief Scientific Officer
Learn More

Stephanie Duncanson, PhD

Senior Director of Corporate Strategy and Business Development
Learn More

Brett Belongia, PhD

Vice President of CMC Operations
Learn More

Ted Ashburn, MD, PhD

President & CEO
Director
Learn More

Christophe Quéva, PhD

Chief Scientific Officer
Learn More

John McCabe, MBA

Chief Financial Officer
Learn More

Stephanie Duncanson, PhD

Senior Director of Corporate Strategy and Business Development
Learn More

John Goldberg, MD

Senior Vice President of Clinical Development
Learn More

Brett Belongia, PhD

Vice President of CMC Operations
Learn More

Lorena Lerner, PhD

Vice President of Molecular Biology
Learn More

Board of Directors

Mitchell H. Finer, PhD

Executive Chairman
Executive Chairman
Learn More

Ted Ashburn, MD, PhD

President & CEO
Director
Learn More

Luke Evnin, PhD

Director
Director
Learn More

Mary Kay Fenton

Director
Director
Learn More

Robert Kirkman, MD

Director
Director
Learn More

Briggs W. Morrison, MD

Director
Director
Learn More

Spencer Nam, MBA

Director
Director
Learn More

Cameron Wheeler, PhD

Director
Director
Learn More

Scientific Advisory Board

Joseph Glorioso III, PhD

Scientific Advisor
Learn More

Thomas Dubensky Jr., PhD

Scientific Advisor
Learn More

Brian Brown, PhD

Scientific Advisor
Learn More

Francisco J. Quintana, PhD

Scientific Advisor
Learn More

Jesse Bloom, PhD

Scientific Advisor
Learn More
Top